When combined with Glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (GLP-1/GIP RAs), these agents exert complementary islet effects and often promote greater weight loss, all with a substantially lower risk of hypoglycaemia than sulfonylureas [2]. The gene discussed is GLP1R; the disease is Hypoglycemia.